NASDAQ:OMIC - Singular Genomics Systems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.75
  • Forecasted Upside: 603.88 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.09
▲ +0.23 (8.04%)

This chart shows the closing price for OMIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Singular Genomics Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMIC

Analyst Price Target is $21.75
▲ +603.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Singular Genomics Systems in the last 3 months. The average price target is $21.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 603.88% upside from the last price of $3.09.

This chart shows the closing price for OMIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Singular Genomics Systems.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2022The Goldman Sachs GroupLower Price TargetBuy$17.00 ➝ $11.00High
1/7/2022Bank of AmericaUpgradeNeutral ➝ Buy$21.00High
1/6/2022UBS GroupLower Price TargetBuy ➝ Buy$32.00 ➝ $25.00High
6/21/2021Bank of AmericaInitiated CoverageNeutral$26.00High
6/21/2021JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
6/21/2021CowenInitiated CoverageOutperformHigh
6/21/2021The Goldman Sachs GroupInitiated CoverageBuy$35.00High
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 4 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Singular Genomics Systems logo
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $3.09
Low: $2.85
High: $3.21

50 Day Range

MA: $4.63
Low: $2.86
High: $6.72

52 Week Range

Now: $3.09
Low: $2.85
High: $33.37

Volume

1,665,777 shs

Average Volume

498,878 shs

Market Capitalization

$218.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Singular Genomics Systems?

The following Wall Street analysts have issued stock ratings on Singular Genomics Systems in the last twelve months: Bank of America Co., Cowen Inc, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for OMIC.

What is the current price target for Singular Genomics Systems?

0 Wall Street analysts have set twelve-month price targets for Singular Genomics Systems in the last year. Their average twelve-month price target is $21.75, suggesting a possible upside of 603.9%.
View the latest price targets for OMIC.

What is the current consensus analyst rating for Singular Genomics Systems?

Singular Genomics Systems currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMIC will outperform the market and that investors should add to their positions of Singular Genomics Systems.
View the latest ratings for OMIC.

How do I contact Singular Genomics Systems' investor relations team?

Singular Genomics Systems' physical mailing address is 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The company's listed phone number is 858-333-7830. The official website for Singular Genomics Systems is singulargenomics.com. Learn More about contacing Singular Genomics Systems investor relations.